Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul;60(7):1009-17.
doi: 10.1007/s00262-011-1014-6. Epub 2011 Apr 12.

The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice

Ronald P Gladue  1 , Timothy Paradis, Susan H Cole, Carol Donovan, Robin Nelson, Robbin Alpert, Joe Gardner, Ed Natoli, Eileen Elliott, Richard Shepard, Vahe Bedian
Affiliations

The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice

Ronald P Gladue et al. Cancer Immunol Immunother. 2011 Jul.

Abstract

CD40 is a member of the TNF family of receptors that has been shown to play a crucial role in enhancing dendritic cell activity and fostering anti-tumor immune responses. In this study, we demonstrate the in vitro properties and in vivo efficacious activity of the CD40 agonist antibody, CP-870,893. CP-870,893 is a fully human, IgG2 antibody that selectively interacts with CD40 at a site distinct from its ligand-binding region with a KD of 0.4 nM. It enhances the expression of MHC class II, CD54, CD86, and CD23 on human B cells in vitro. CP-870,893 also enhances dendritic cell activity as evidenced by cytokine secretion (IL-12, IL-23, IL-8), the upregulation of CD86 and CD83, and the ability to prime T cells to secrete IFNγ. In SCID-beige mice, a single parenteral injection of CP-870,893 was therapeutically effective against several CD40(pos) human tumors (B-cell lymphoma, breast, colon, and prostate) indicating direct effects on tumor cell survival and/or growth. When mice were co-implanted with human T cells and dendritic cells, the activity of CP-870,893 against CD40(pos) tumors increased, and efficacy was also observed against CD40(neg) and CD40(low) tumors demonstrating the ability of CP-870,893 to enhance anti-tumor immune function in vivo. These studies suggest that CP-870,893 has the potential to be efficacious against a wide range of tumor types through both direct and immune-mediated effects.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Effects of CP-870,893 on cell surface marker upregulation on human CD19+ B cells and human mDC. a CP-870,893 or anti-KLH control was added to heparinized human whole blood for 24 h, and cell surface upregulation of various markers was determined using flow cytometry by gating on CD19+ B cells. Each data point is the mean of >6 experiments using different human donors. b mDCs were prepared as described in the materials and methods and incubated with various concentrations of CP-870,893 or an anti-KLH control antibody for 24 h. The upregulation of cell surface markers was determined by flow cytometry. Each data point is the mean of at least 6 studies
Fig. 2
Fig. 2
CP-870,893 prevents mortality induced by several B-cell lymphomas. a CP-870,893 was administered i.p. followed by the injection of 5 × 106 Daudi cells (IV). Mortality was monitored for 50 days. The MST was 25 days for the anti-KLH group and 48 days for the animals treated with CP-870,893. The group size was 10 animals per group and the study is representative of 5 separate studies. b CP-870,893 was administered i.p. at the time of s.c. tumor challenge with the B-cell lymphoma Daudi. Tumor size is represented in mm2. Each data point is the mean ± the SE for 5 animals per group and is representative of 3 separate experiments. c CP-870,893 was administered i.p. at the time of s.c. tumor challenge with the B-cell lymphoma Jijoye. Each data point refers to the mean tumor size in mm2 ± the SE for 5 animals per group. The study is representative of 3 separate studies
Fig. 3
Fig. 3
Effect of human T cells and mDCs on the in vivo activity of CP-870,893 in SCID-beige mice. a Dose-dependant inhibition of the CD40pos tumor Raji by CP-870,893 in the presence or absence of human T cells and mDC. CP-870,893 was administered i.p. at the time of s.c. tumor challenge. The data points represent the tumor size (mm2) for each individual animal taken on day 21 after tumor challenge. The mean tumor size for each treatment group (N = 10) is indicated by the horizontal line. The study is representative of at least 3 separate experiments. Significance is indicated as compared to the anti-KLH control. Significance in comparing groups with and without T cells and mDC are as follows: 0.1 mg/kg group P < 0.01; 0.01 mg/kg group P < 0.01; 0.001 mg/kg group P = 0.0103; 0.0001 mg/kg group P = 0.26. b Dose-dependant inhibition of the CD40neg tumor K562 by CP-870,893 in the presence human T cells and mDC. Animals received a single injection (IP) of various dose levels of CP-870,893 or 10 mg/kg anti-KLH at the time of s.c. tumor challenge. The data are representative of 3 experiments
Fig. 4
Fig. 4
CP-870,893 prevents the growth of the human breast tumor cell line, BT 474 in the presence of human T cells and mDCs. BT474 tumor cells were administered s.c. along with human T cells and mDCs. a CP-870,893 was administered i.p. at the time of tumor challenge. Each data point refers to the tumor size of an individual animal measured on day 53 after challenge, a time when control animals reach a tumor size where they were euthanized. The horizontal lines represent the mean tumor size. b CP-870,893 was administered at a dose of 1.0 mg/kg once tumors reached a size of 100 mm2. Each data point refers to the tumor size of an individual animal measured on day 52 after challenge, a time when control animals reach a tumor size where they were euthanized. The horizontal lines represent the mean tumor size for all animals in that group
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chaudhuri D, Suriano R, Mittelman A, Tiwari RK. Targeting the immune system in cancer. Curr Pharm Biotechnol. 2009;10:166–184. doi: 10.2174/138920109787315114. - DOI - PubMed
    1. Lustgarten J. Cancer, aging and immunotherapy: lessons learned from animal models. Cancer Immunol Immunother. 2009;58:1979–1989. - PMC - PubMed
    1. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009;229:152–172. doi: 10.1111/j.1600-065X.2009.00782.x. - DOI - PMC - PubMed
    1. Diehl L, Den Boer AT, van der Voort EI, Melief CJ, Offringa R, Toes RE. The role of CD40 in peripheral T cell tolerance and immunity. J Mol Med. 2000;78:363–371. doi: 10.1007/s001090000126. - DOI - PubMed
    1. Sartorius R, D’Apice L, Barba P, et al. Induction of human NK cell-mediated cytotoxicity by CD40 triggering on antigen presenting cells. Cell Immunol. 2003;221:81–88. doi: 10.1016/S0008-8749(03)00060-1. - DOI - PubMed